Zyprexa works, but may cause profound sedation, FDA staff says

An FDA official has issued a memo citing reports of excessive sedation in some patients who received a long-acting, injectable form of Zyprexa, Eli Lilly and Co.'s blockbuster schizophrenia drug. The Indianapolis-based drugmaker says the formulation offers advantages that outweigh safety concerns, which it says "are manageable with appropriate labeling and risk-minimization activities."

View Full Article in:

Wall Street Journal (free content), The · Indianapolis Star (tiered subscription model), The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA